Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers

References

• De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat. 2015;20:39–70.
   Google Scholar
• Diasio RB, Innocenti F, Offer SM. Pharmacogenomic-guided therapy in colorectal cancer. Clin Pharmacol Ther. 2021;110(3):616–625.
   Google Scholar
• Knikman JE, Gelderblom H, Beijnen JH, et al. Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther. 2021;109(3):591–604.
   Google Scholar
• Saif MW. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 2011;10(2):159–169.
   Google Scholar
• Sugihara K, Ohtsu A, Shimada Y, et al. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer. 2012;11(2):127–137.
   Google Scholar
• Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216.
   Google Scholar
• Lunenburg CATC, van der Wouden CH, Nijenhuis M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508–517.
   Google Scholar
• Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, et al. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol. 1995;14(1):1–6.
   Google Scholar
• Hamzic S, Aebi S, Joerger M, et al. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss group of pharmacogenomics and personalised therapy. Swiss Med Wkly [ Internet]. 2020 [cited 2022 Jan 14]. Available from: https://smw.ch/article/doi/smw.2020.20375
   Google Scholar
• Nie Q, Shrestha S, Tapper EE, et al. Quantitative Contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther. 2017;102(4):662–670.
   Google Scholar
• Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459–1467.
   Google Scholar
• Falvella FS, Cheli S, Martinetti A, et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. Br J Clin Pharmacol. 2015;80(3):581–588.
   Google Scholar
• Joerger M, Huitema ADR, Boot H, et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):763–772.
   Google Scholar
• Pellicer M, García-González X, García MI, et al. Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol Res. 2017;120:133–137.
   Google Scholar
• Sharma BB, Rai K, Blunt H, et al. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021;26(12):1008–1016.
   Google Scholar
• Liu D, Li J, Gao J, et al. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer [Internet]. 2017;17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480170
   Google Scholar
• Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17(10):3455–3468.
   Google Scholar
• Isaakidou A, Gazouli M, Aravantinos G, et al. Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. J Cancer Res Ther. 2016;12(1):193–197.
   Google Scholar
• Castro-Rojas CA, Esparza-Mota AR, Hernandez-Cabrera F, et al. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer. Drug Metab Pers Ther. 2017;32(4):209–218.
   Google Scholar
• Jennings BA, Kwok CS, Willis G, et al. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics. 2012;22(4):290–304.
   Google Scholar
• Wang Y-C, Xue H-P, Wang Z-H, et al. An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. Mol Biol Rep. 2013;40(7):4637–4644.
   Google Scholar
• Wang Y, Shen L, Xu N, et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol. 2012;18(45):6635–6644.
   Google Scholar
• Madi A, Fisher D, Maughan TS, et al. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018;102:31–39.
   Google Scholar
• Budai B, Komlósi V, Adleff V, et al. Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Pharmacogenet Genomics. 2012;22(1):69–72.
   Google Scholar
• Hong J, Han S-W, Ham HS, et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol. 2011;67(6):1323–1331.
   Google Scholar
• Kumamoto K, Ishibashi K, Okada N, et al. Polymorphisms of GSTP1, ERCC2 and TS‑3’UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncol Lett. 2013;6(3):648–654.
   Google Scholar
• Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031–1039.
   Google Scholar
• García-González X, Cortejoso L, García MI, et al. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget. 2015;6(8):6422–6430.
   Google Scholar
• Dong S-Q, Wang T-M, Zhang J-B, et al. Polymorphisms in TYMS for prediction of capecitabine-induced hand-foot syndrome in Chinese patients with colorectal cancer. Cancer Res Treat. 2020;53(3):724–732.
   Google Scholar
• Cecchin E, De Mattia E, Ecca F, et al. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18–40.
   Google Scholar
• De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer. 2009;45(8):1333–1351.
   Google Scholar
• Zhong L, He X, Zhang Y, et al., Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidine-based chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2018;9(58):31291–31301.
   Google Scholar
• Zintzaras E, Ziogas DC, Kitsios GD, et al. MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis. Pharmacogenomics. 2009;10(8):1285–1294.
   Google Scholar
• Ramos-Esquivel A, Chinchilla-Monge R, Abbas J, et al. C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer. Pharmacogenet Genomics. 2021;31(9):191–199.
   Google Scholar
• Ramos-Esquivel A, Chinchilla R, Valle M. Association of C677T and A1298C MTHFR polymorphisms and fluoropyrimidine-induced toxicity in mestizo patients with metastatic colorectal cancer. Anticancer Res. 2020;40(8):4263–4270.
   Google Scholar
• van Huis-tanja LH, Gelderblom H, Punt CJA, et al. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics. 2013;23(4):208–218.
   Google Scholar
• Thorn CF, Marsh S, Carrillo MW, et al. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21(4):237–242.
   Google Scholar
• Chen Q, Meng F, Wang L, et al. A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients. Sci Rep. 2017;7(1):7059.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting Tas-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017;86:197–206.
   Google Scholar
• O’Donnell PH, Stark AL, Gamazon ER, et al. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012;118(16):4063–4073.
   Google Scholar
• van Huis-tanja LH, Ewing E, van der Straaten RJHM, et al. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015;25(6):279–288.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Genetic variants of DNA repair-related genes predict efficacy of Tas-102 in patients with refractory metastatic colorectal cancer. Ann Oncol. 2017;28(5):1015–1022.
   Google Scholar
• Chen Q, Mao Y, Meng F, et al. Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression. Oncotarget. 2017;8(43):74312–74319.
   Google Scholar
• Lam SW, Guchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. 2016;50:9–22.
   Google Scholar
• De Mattia E, Cecchin E, Polesel J, et al. UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. Liver Int. 2017;37(9):1345–1353.
   Google Scholar
• rs3064744 RefSNP Report - dbSNP - NCBI [Internet]. [cited 2022 Jan 17]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs3064744?horizontal_tab=true
   Google Scholar
• Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24(19):3061–3068.
   Google Scholar
• Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: a prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022;162:148–157.
   Google Scholar
• Liu X-H, Lu J, Duan W, et al., Predictive value of UGT1A1*28 polymorphism in irinotecan-based chemotherapy. J Cancer. 2017;8(4):691–703.
   Google Scholar
• Yang Y, Zhou M, Hu M, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: a meta-analysis. Asia Pac J Clin Oncol. 2018;14(5):e479–e489.
   Google Scholar
• ONIVYDE pegylated liposomal, INN-irinotecan anhydrous free base; 2019. [citedJun 24 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/onivyde-pegylated-liposomal-epar-product-information_en.pdf.
   Google Scholar
• Atasilp C, Chansriwong P, Sirachainan E, et al. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Sci Rep. 2020;10(1):13486.
   Google Scholar
• Miyata Y, Touyama T, Kusumi T, et al. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2016;21(4):696–703.
   Google Scholar
• Dias MM, McKinnon RA, Sorich MJ. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics. 2012;13(8):889–899.
   Google Scholar
• Dias MM, Pignon J-P, Karapetis CS, et al. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J. 2014;14(5):424–431.
   Google Scholar
• Liu X, Cheng D, Kuang Q, et al. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLOS ONE. 2013;8(3):e58489.
   Google Scholar
• Zhu X, Ma R, Ma X, et al. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis. Biosci Rep. 2020;40(10): BSR20200576. DOI:10.1042/BSR20200576
   Google Scholar
• Chen S, Hua L, Feng C, et al. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang. BMC Gastroenterol. 2020;20(1):96.
   Google Scholar
• Fujii H, Yamada Y, Watanabe D, et al. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol. 2019;83(1):123–129.
   Google Scholar
• Yu Q, Zhang T, Xie C, et al. UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. Cancer Chemother Pharmacol. 2018;82(1):87–98.
   Google Scholar
• Riera P, Artigas-Baleri A, Salazar J, et al. ABCB1 genetic variants as predictors of irinotecan-induced severe gastrointestinal toxicity in metastatic colorectal cancer patients. Front Pharmacol. 2020;11:973.
   Google Scholar
• Teft WA, Welch S, Lenehan J, et al. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer. 2015;112(5):857–865.
   Google Scholar
• Cortejoso L, García MI, García-Alfonso P, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013;71(6):1463–1472.
   Google Scholar
• Salvador-Martín S, García-González X, García MI, et al. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacol Res. 2018;136:133–139.
   Google Scholar
• Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631–646.
   Google Scholar
• De Mattia E, Toffoli G, Polesel J, et al. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013;23(10):549–557.
   Google Scholar
• Akiyama Y, Fujita K, Ishida H, et al. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet. 2012;27(3):325–335.
   Google Scholar
• Chen S, Villeneuve L, Jonker D, et al. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015;25(12):573–583.
   Google Scholar
• Di Martino MT, Arbitrio M, Leone E, et al. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 2011;12(9):780–787.
   Google Scholar
• Rhodes KE, Zhang W, Yang D, et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metab Lett. 2007;1(1):23–30.
   Google Scholar
• Huang L, Zhang T, Xie C, et al. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLOS ONE. 2013;8(10):e77223.
   Google Scholar
• Riera P, Salazar VAC, Virgili AC, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. Br J Clin Pharmacol [Internet]. 2018;84:1389–1392. [cited 2021 Nov 30]. Available from: https://scite.ai/reports/relevance-of-cyp3a4-20-ugt1a1-37-9OlaXgG
   Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8(4):94.
   Google Scholar
• Dong N, Meng F, Wu Y, et al. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. Tumour Biol. 2015;36(10):7691–7698.
   Google Scholar
• McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28(20):3227–3233.
   Google Scholar
• Wang D, Zhang X, Zhang Y, et al. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer. OTT. 2018;11:8083–8088.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018;18(5):623–632.
   Google Scholar
• Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer. 2012;106(1):18–24.
   Google Scholar
• Paolicchi E, Vivaldi C, De Gregorio V, et al. Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients. Oncology. 2016;91(5):283–288.
   Google Scholar
• Haenisch S, Cascorbi I. Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics. 2012;4(4):369–381.
   Google Scholar
• Boni V, Zarate R, Villa JC, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J. 2011;11(6):429–436.
   Google Scholar
• Lampropoulou D-I, Aravantinos G, Katifelis H, et al. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. Cancer Biomarkers. 2019;25(2):213–221.
   Google Scholar
• Lampropoulou D-I, Aravantinos G, Laschos K, et al. MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. Int J Colorectal Dis. 2019;34(11):1871–1877.
   Google Scholar
• Branca JJV, Carrino D, Gulisano M, et al. Oxaliplatin-induced neuropathy: genetic and epigenetic profile to better understand how to ameliorate this side effect. Front Mol Biosci. 2021;8:166.
   Google Scholar
• Huang KM, Leblanc AF, Uddin ME, et al. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020;130(9):4601–4606.
   Google Scholar
• Di Cesare Mannelli L, Zanardelli M, Landini I, et al. Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: possible aid in chemotherapy induced neuropathy. Free Radic Biol Med. 2016;93:67–76.
   Google Scholar
• Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14(8):1767–1776.
   Google Scholar
• Qian -Y-Y, Liu X-Y, Wu Q, et al. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. Asian Pac J Cancer Prev. 2014;15(19):8383–8390.
   Google Scholar
• Shahnam A, Ridha Z, Wiese MD, et al., Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics. 2016;17(15):1725–1732.
   Google Scholar
• Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17(6):1632–1640.
   Google Scholar
• Liu Z, Kong J, Kong Y, et al. Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer. Adv Clin Exp Med. 2019;28(11):1459–1468.
   Google Scholar
• Gordon MA, Zhang W, Yang D, et al. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics. 2011;12(1):27–39.
   Google Scholar
• Kjersem JB, Thomsen M, Guren T, et al. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J. 2016;16(3):272–279.
   Google Scholar
• Chen J, Luo X, Xie G, et al. Functional analysis of SNPs in the ERCC5 promoter in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy. Medicine (Baltimore). 2016;95(19):e3652.
   Google Scholar
• Kong J, Liu Z, Cai F, et al. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China. Clinics (Sao Paulo). 2018;73:e455.
   Google Scholar
• Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis. 2004;25(5):757–763.
   Google Scholar
• Wang Y, Spitz MR, Zhu Y, et al. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst). 2003;2(8):901–908.
   Google Scholar
• Wu H, Xu C, Chen G, et al. X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. J Gastroenterol Hepatol. 2014;29(5):926–933.
   Google Scholar
• Ye F, Liu Z, Tan A, et al. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(3):733–740.
   Google Scholar
• Hu X, Qin W, Li S, et al. Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy. Cancer Manag Res. 2019;11:285–297.
   Google Scholar
• Monzo M, Moreno I, Navarro A, et al. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine. Oncology. 2007;72(5–6):364–370.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Single nucleotide polymorphisms in MiRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab: analysis of the TRIBE trial. Cancers (Basel). 2020;12(7):1742.
   Google Scholar
• Kap EJ, Richter S, Rudolph A, et al. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Pharmacogenet Genomics. 2014;24(7):340–347.
   Google Scholar
• Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25(10):1247–1254.
   Google Scholar
• Inada M, Sato M, Morita S, et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther. 2010;48(11):729–734.
   Google Scholar
• Paré L, Marcuello E, Altés A, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer. 2008;99(7):1050–1055.
   Google Scholar
• Peng Z, Wang Q, Gao J, et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2013;72(2):305–314.
   Google Scholar
• Liu H, Shi W, Zhao L, et al. Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports. OTT. 2016;9:3683–3694.
   Google Scholar
• Boige V, Mendiboure J, Pignon J-P, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28(15):2556–2564.
   Google Scholar
• Huang M-Y, Huang M-L, Chen M-J, et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics. 2011;21(1):18–25.
   Google Scholar
• Wu H, Kang H, Liu Y, et al. Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis. Pharmacogenomics. 2013;14(8):897–911.
   Google Scholar
• Yuan T, Deng S, Chen M, et al. Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Cancer Epidemiol. 2011;35(2):170–174.
   Google Scholar
• Zhao J, Li W, Zhu D, et al. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med Oncol. 2014;31(1):802.
   Google Scholar
• Labriet A, De Mattia E, Cecchin E, et al. Improved progression-free survival in irinotecan-treated metastatic colorectal cancer patients carrying the HNF1A coding variant p.I27L. Front Pharmacol. 2017;8:712.
   Google Scholar
• Watts K, Wills C, Madi A, et al. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. Int J Cancer. 2021;149(9):1713–1722.
   Google Scholar
• Nichetti F, Falvella FS, Miceli R, et al. Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? Pharmacogenomics J. 2019;19(5):465–472.
   Google Scholar
• Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119(19):3570–3577.
   Google Scholar
• Cecchin E, De Mattia E, Toffoli G. Nuclear receptors and drug metabolism for the personalization of cancer therapy. Expert Opin Drug Metab Toxicol. 2016;12(3):291–306.
   Google Scholar
• De Mattia E, Dreussi E, Cecchin E, et al. Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects? Pharmacogenomics. 2013;14(16):2035–2054.
   Google Scholar
• De Mattia E, Cecchin E, Roncato R, et al. Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. Pharmacogenomics. 2016;17(14):1547–1571.
   Google Scholar
• Raynal C, Pascussi J-M, Leguelinel G, et al. Pregnane × Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010;9(1):46.
   Google Scholar
• Basseville A, Preisser L, de Carné Trécesson S, et al. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer. 2011;10(1):80.
   Google Scholar
• Mbatchi LC, Robert J, Ychou M, et al. Effect of single nucleotide polymorphisms in the xenobiotic-sensing receptors NR1I2 and NR1I3 on the pharmacokinetics and toxicity of irinotecan in colorectal cancer patients. Clin Pharmacokinet. 2016;55(9):1145–1157.
   Google Scholar
• De Mattia E, Polesel J, Roncato R, et al. Germline polymorphisms in the nuclear receptors PXR and VDR as novel prognostic markers in metastatic colorectal cancer patients treated with FOLFIRI. Front Oncol. 2019;9:1312.
   Google Scholar
• De Mattia E, Cecchin E, Montico M, et al. Association of STAT-3 rs1053004 and VDR rs11574077 with FOLFIRI-related gastrointestinal toxicity in metastatic colorectal cancer patients. Front Pharmacol. 2018;9:367.
   Google Scholar
• Bailly C. Irinotecan:25 years of cancer treatment. Pharmacol Res. 2019;148:104398.
   Google Scholar
• Wong DVT, Ribeiro-Filho HV, Wanderley CWS, et al. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemother Pharmacol. 2019;84(2):287–298.
   Google Scholar
• Wong DVT, Holanda RBF, Cajado AG, et al. TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea. Br J Pharmacol. 2021;178(20):4193–4209.
   Google Scholar
• Fiore PF, Matteo SD, Tumino N, et al. Interleukin-15 and cancer: some solved and many unsolved questions. J Immunother Cancer. 2020;8(2):e001428.
   Google Scholar
• De Mattia E, Polesel J, Roncato R, et al. IL15RA and SMAD3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with FOLFIRI therapy: a new paradigm. Cancers (Basel). 2021;13(7):1705.
   Google Scholar
• De Re V, Caggiari L, De Zorzi M, et al. Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS ONE. 2014;9(1):e84940.
   Google Scholar
• Garziera M, Bidoli E, Cecchin E, et al. HLA-G 3’UTR polymorphisms impact the prognosis of stage II-III CRC patients in fluoropyrimidine-based treatment. PLoS ONE. 2015;10(12):e0144000.
   Google Scholar
• Samadi R, Mojarad EN, Molaei M, et al. Clinical value of Human Leucocyte Antigen G (HLA-G) expression in the prognosis of colorectal cancer. Int J Cancer Manage [Internet]. 2017;10. [cited 2019 Feb 18]. Available from: http://ijcancerprevention.com/en/articles/9346.html
   Google Scholar
• Scarabel L, Garziera M, Fortuna S, et al. Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy. Sci Rep. 2020;10(1):8773.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. Pharmacogenomics J. 2021;21(3):285–295.
   Google Scholar
• Labriet A, Lévesque É, Cecchin E, et al. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. Sci Rep. 2019;9(1):13008.
   Google Scholar
• Samalin E, de la FC, Thézenas S, et al. Sorafenib plus irinotecan combination in patients with RAS-mutated metastatic colorectal cancer refractory to standard combined chemotherapies: a multicenter, randomized phase 2 trial (NEXIRI-2/PRODIGE 27). Clin Colorectal Cancer. 2020;19(4):301–310.e1.
   Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72.
   Google Scholar
• Arai H, Xiao Y, Loupakis F, et al. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. J Immunother Cancer. 2020;8(2):e001714.
   Google Scholar
• Gray V, Briggs S, Palles C, et al. Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. J Natl Cancer Inst. 2019;111(8):828–836.
   Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):iii1–9.
   Google Scholar
• Cao Y, Tan A, Gao F, et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24(6):677–685.
   Google Scholar
• Adadw W, Arnold D, Grothey AAG, et al. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev. 2009;CD005392. DOI:10.1002/14651858.CD005392.pub3.
   Google Scholar
• Dean L, Kane M. Cetuximab therapy and RAS and BRAF genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical genetics summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. [cited 2022 Jun 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK564547/
   Google Scholar
• Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–267.
   Google Scholar
• Loupakis F, Cremolini C, Fontanini G, et al. Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Ther Adv Med Oncol. 2009;1(3):167–181.
   Google Scholar
• Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res. 2021;40(1):328.
   Google Scholar
• Popa C, Lungulescu C, Ianoși S, et al. Molecular profiling of EGFR status to identify skin toxicity in colorectal cancer: a clinicopathological review. Curr Health Sci J. 2019;45(2):127–133.
   Google Scholar
• wẁw.ema.eu. Erbitux [Internet]. European Medicines Agency; 2018 [cited 2022 Jan 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux
   Google Scholar
• Ferris RL, Lenz H-J, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48–60.
   Google Scholar
• van Sorge NM, van der Pol W-L, van de Winkel JGJ. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens. 2003;61(3):189–202.
   Google Scholar
• Liu G, Tu D, Lewis M, et al. Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clin Cancer Res. 2016;22(10):2435–2444.
   Google Scholar
• Shepshelovich D, Townsend AR, Espin-Garcia O, et al. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018;7(11):5478–5487.
   Google Scholar
• Geva R, Vecchione L, Kalogeras KT, et al. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2015;64(6):921–928.
   Google Scholar
• Kjersem JB, Skovlund E, Ikdahl T, et al. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin ± cetuximab. BMC Cancer. 2014;14(1):340.
   Google Scholar
• Park SJ, Hong YS, Lee J-L, et al. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology. 2012;82(2):83–89.
   Google Scholar
• Ying H-Q, Wang F, Chen X-L, et al., FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. Oncotarget. 2015;6(29):28071–28083.
   Google Scholar
• Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27(7):1122–1129.
   Google Scholar
• Calemma R, Ottaiano A, Trotta AM, et al. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med. 2012;10(1):232.
   Google Scholar
• Lo Nigro C, Ricci V, Vivenza D, et al. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol. 2016;8(2):222–230.
   Google Scholar
• Maeda H, Hazama S, Iwamoto S, et al. Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin-based combination therapy in metastatic colorectal cancer: analysis of data from two clinical trials. Oncol Lett. 2019;18(5):4555–4562.
   Google Scholar
• Negri FV, Musolino A, Naldi N, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependent cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J. 2014;14(1):14–19.
   Google Scholar
• Trotta AM, Ottaiano A, Romano C, et al. Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy. Cancer Immunol Res. 2016;4(4):366–374.
   Google Scholar
• Lu X, Chen X, Sun J, et al. Polymorphism in epidermal growth factor is related to clinical outcomes of metastatic colorectal cancer patients treated with cetuximab: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(7):10929–10937.
   Google Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120(5):635–647.
   Google Scholar
• Saridaki Z, Weidhaas JB, Lenz H-J, et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage Cetuximab/Panitumumab monotherapy. Clin Cancer Res. 2014;20(17):4499–4510.
   Google Scholar
• Zhang W, Winder T, Ning Y, et al. A let-7 microRNA-binding site polymorphism in 3’-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104–109.
   Google Scholar
• Kjersem JB, Ikdahl T, Guren T, et al. Let-7 miRNA-binding site polymorphism in the KRAS 3’UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin ± cetuximab. BMC Cancer. 2012;12(1):534.
   Google Scholar
• Sebio A, Paré L, Páez D, et al. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3’-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2013;23(3):142–147.
   Google Scholar
• Langevin SM, Christensen BC. Let-7 micro RNA -binding-site polymorphism in the 3′ UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. Cancer Med. 2014;3(5):1385–1395.
   Google Scholar
• Ying H-Q, Wang F, B-s H, et al. The involvement of Kras gene 3’-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. Onco Targets Ther. 2014;7:1487–1496.
   Google Scholar
• Moriai T, Kobrin MS, Hope C, et al. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci U S A. 1994;91(21):10217–10221.
   Google Scholar
• Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004;64(24):9139–9143.
   Google Scholar
• Gebhardt F, Zänker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem. 1999;274(19):13176–13180.
   Google Scholar
• Spindler K-LG, Nielsen JN, Ornskov D, et al. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol. 2007;46(8):1113–1117.
   Google Scholar
• Graziano F, Ruzzo A, Loupakis F, et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol. 2008;26(9):1427–1434.
   Google Scholar
• Loupakis F, Antoniotti C, Cremolini C, et al. Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. Pharmacogenomics J. 2014;14(4):322–327.
   Google Scholar
• Lurje G, Nagashima F, Zhang W, et al. Polymorphisms in Cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008;14(23):7884–7895.
   Google Scholar
• Hsieh -Y-Y, Tzeng C-H, Chen M-H, et al. Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci. 2012;103(4):791–796.
   Google Scholar
• Morgen EK, Lenz H-J, Jonker DJ, et al., Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. Pharmacogenomics J. 2017;17(6):535–542.
   Google Scholar
• Dahan L, Norguet E, Etienne-Grimaldi M-C, et al. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer. 2011;11(1):496.
   Google Scholar
• Madi A, Fisher D, Maughan TS, et al. Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. J Med Genet. 2017;54(8):567–571.
   Google Scholar
• Vallböhmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005;23(15):3536–3544.
   Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384.
   Google Scholar
• Okazaki S, Stintzing S, Sunakawa Y, et al. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer. 2017;141(6):1222–1230.
   Google Scholar
• Sebio A, Stintzing S, Heinemann V, et al. A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J. 2018;18(1):43–48.
   Google Scholar
• Pander J, van Huis-tanja L, Böhringer S, et al. Genome wide association study for predictors of progression free survival in patients on capecitabine, oxaliplatin, bevacizumab and cetuximab in first-line therapy of metastatic colorectal cancer. PLoS One. 2015;10(7):e0131091.
   Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   Google Scholar
• Lee YC, Michael M, Zalcberg JR. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opin Investig Drugs. 2015;24(10):1307–1320.
   Google Scholar
• Balasubramanian SP, Brown NJ, Reed MWR. Role of genetic polymorphisms in tumour angiogenesis. Br J Cancer. 2002;87(10):1057–1065.
   Google Scholar
• Sohn BS, Park SJ, Kim JE, et al. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer. Oncology. 2014;87(5):280–292.
   Google Scholar
• Cui W, Li F, Yuan Q, et al. Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab. Oncotarget. 2017;8(62):105472–105478.
   Google Scholar
• Loupakis F, Ruzzo A, Salvatore L, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11(1):247.
   Google Scholar
• Barat A, Smeets D, Moran B, et al. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Sci Rep. 2020;10(1):9778.
   Google Scholar
• Di Salvatore M, Pietrantonio F, Orlandi A, et al. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. Oncotarget. 2017;8(10):16887–16898.
   Google Scholar
• Loupakis F, Cremolini C, Yang D, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One. 2013;8(7):e66774.
   Google Scholar
• Ulivi P, Scarpi E, Passardi A, et al. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. J Transl Med. 2015;13(1):258.
   Google Scholar
• Sibertin-Blanc C, Mancini J, Fabre A, et al. Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis. 2015;47(4):331–337.
   Google Scholar
• Gerger A, El-Khoueiry A, Zhang W, et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011;17(17):5783–5792.
   Google Scholar
• Garziera M, Scarabel L, Toffoli G. Hypoxic modulation of HLA-G expression through the metabolic sensor HIF-1 in human cancer cells. J Immunol Res. 2017;2017:4587520.
   Google Scholar
• Chionh F, Gebski V, Al-Obaidi SJ, et al. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Sci Rep. 2022;12(1):1238.
   Google Scholar
• Hansen TF, dePont CR, Andersen RF, et al. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis. 2012;27(6):715–720.
   Google Scholar
• Giampieri R, Salvatore L, Del Prete M, et al. Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Sci Rep. 2016;6(1):25195.
   Google Scholar
• Conde E, Earl J, Crespo-Toro L, et al. Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: REFRAME molecular study. Cancers (Basel). 2021;13(7):1710.
   Google Scholar
• Berger MD, Stintzing S, Heinemann V, et al. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017;28(11):2780–2785.
   Google Scholar
• Gore AV, Swift MR, Cha YR, et al. Rspo1/Wnt signaling promotes angiogenesis via Vegfc/Vegfr3. Development. 2011;138(22):4875–4886.
   Google Scholar
• Berger MD, Ning Y, Stintzing S, et al. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Eur J Cancer. 2020;131:89–97.
   Google Scholar
• Volz NB, Stintzing S, Zhang W, et al. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J. 2015;15(1):69–76.
   Google Scholar
• Morita S, Uehara K, Nakayama G, et al. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2013;71(2):405–411.
   Google Scholar
• Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258(5089):1798–1801.
   Google Scholar
• Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2009;284(10):6038–6042.
   Google Scholar
• Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107(5):1761–1767.
   Google Scholar
• Guleng B, Tateishi K, Ohta M, et al. Blockade of the Stromal Cell–Derived Factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth Factor–Independent manner. Cancer Res. 2005;65(13):5864–5871.
   Google Scholar
• Matsusaka S, Cao S, Hanna DL, et al. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 2017;17(6):543–550.
   Google Scholar
• Barbera-Guillem E, Nyhus JK, Wolford CC, et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002;62(23):7042–7049.
   Google Scholar
• Sunakawa Y, Stintzing S, Cao S, et al. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. Ann Oncol. 2015;26(12):2450–2456.
   Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Gene polymorphisms in the CCL5/CCR5 pathway as a genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with Regorafenib. Clin Colorectal Cancer. 2018;17(2):e395–e414.
   Google Scholar
• Suenaga M, Cao S, Zhang W, et al. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. Int J Cancer. 2019;144(10):2567–2577.
   Google Scholar
• Suenaga M, Zhang WU, Mashima T, et al. Potential molecular cross talk among CCR5 pathway predicts regorafenib responsiveness in metastatic colorectal cancer patients. Cancer Genomics Proteomics. 2021;18(3):317–324.
   Google Scholar
• Tokunaga R, Cao S, Naseem M, et al. Prognostic effect of adenosine-related genetic variants in metastatic colorectal cancer treated with bevacizumab-based chemotherapy. Clin Colorectal Cancer. 2019;18(1):e8–e19.
   Google Scholar
• Johnson CM, Lyle EA, Omueti KO, et al. Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol. 2007;178(12):7520–7524.
   Google Scholar
• Schirripa M, Zhang W, Heinemann V, et al. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017;141(2):383–392.
   Google Scholar
• Matsusaka S, Zhang W, Cao S, et al. TWIST1 polymorphisms predict survival in patients with metastatic colorectal cancer receiving first-line bevacizumab plus oxaliplatin-based chemotherapy. Mol Cancer Ther. 2016;15(6):1405–1411.
   Google Scholar
• Yang M-H, M-z W, Chiou S-H, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295–305.
   Google Scholar
• Burgermeister E, Battaglin F, Eladly F, et al. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. EBioMedicine. 2019;45:139–154.
   Google Scholar
• Koyanagi S, Kuramoto Y, Nakagawa H, et al. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res. 2003;63(21):7277–7283.
   Google Scholar
• Miyamoto Y, Schirripa M, Suenaga M, et al. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS One. 2020;15(9):e0239439.
   Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase iii randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. JCO. 2012;30(28):3499–3506.
   Google Scholar
• Obermannová R, Van Cutsem E, Yoshino T, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol. 2016;27(11):2082–2090.
   Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508.
   Google Scholar
• Lambrechts D, Thienpont B, Thuillier V, et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br J Cancer. 2015;113(7):1027–1034.
   Google Scholar
• Toffoli G, Innocenti F, Polesel J, et al. The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice. Clin Pharmacol Ther. 2019;105(4):994–1002.
   Google Scholar
• Roncato R, Cecchin E, Montico M, et al. Cost evaluation of irinotecan-related toxicities associated with the UGT1A1*28 patient genotype. Clin Pharmacol Ther. 2017;102(1):123–130.
   Google Scholar
• Di Caro G, Marchesi F, Laghi L, et al. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med. 2013;17(9):1088–1095.
   Google Scholar
• Kanterman J, Sade-Feldman M, Biton M, et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 2014;74(21):6022–6035.
   Google Scholar
• Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061.
   Google Scholar
• Maeda K, Hazama S, Tokuno K, et al. Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. Anticancer Res. 2011;31(12):4569–4574.
   Google Scholar
• Asleh K, Brauer HA, Sullivan A, et al. Predictive biomarkers for adjuvant capecitabine benefit in early-stage triple-negative breast cancer in the FinXX clinical trial. Clin Cancer Res. 2020;26(11):2603–2614.
   Google Scholar
• Lee SY, Lee DY, Kang JH, et al. Relationship between gut microbiota and colorectal cancer: probiotics as a potential strategy for prevention. Food Res Int. 2022;156:111327.
   Google Scholar
• Wang J, Huang Y. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Curr Drug Discov Technol. 2007;4(1):59–68.
   Google Scholar
• Fernández-Contreras M-E, Sánchez-Hernández JJ, Guijarro M, et al. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep. 2010;23(5):1393–1400.
   Google Scholar
• Fariña-Sarasqueta A, Gosens MJEM, Moerland E, et al. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Cell Oncol (Dordr). 2011;34(4):327–335.
   Google Scholar
• Zhang W, Press OA, Haiman CA, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007;25(24):3726–3731.
   Google Scholar
• Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–291.
   Google Scholar
• Goldstein DB, Allen A, Keebler J, et al. Sequencing studies in human genetics: design and interpretation. Nat Rev Genet. 2013;14(7):460–470.
   Google Scholar
• Xiao Q, Zhou Y, Winter S, et al. Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. Int J Cancer. 2020;146(9):2475–2487.
   Google Scholar
• Zhou Y, Dagli Hernandez C, Lauschke VM. Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier. Br J Cancer. 2020;123(12):1782–1789.
   Google Scholar
• Palmirotta R, Lovero D, Delacour H, et al. Rare dihydropyrimidine dehydrogenase variants and toxicity by floropyrimidines: a case report. Front Oncol. 2019;9:139.
   Google Scholar
• García-González X, Kaczmarczyk B, Abarca-Zabalía J, et al. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. Cancer Chemother Pharmacol. 2020;86(1):45–54.
   Google Scholar
• Henricks LM, Siemerink EJM, Rosing H, et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. Int J Cancer. 2018;142(2):424–430.
   Google Scholar
• Ly RC, Schmidt RE, and Kiel PJ, et al. Severe capecitabine toxicity associated with a rare DPYD variant identified through whole-genome sequencing. JCO Precis Oncol. 2020;4:632–638.
   Google Scholar